McKesson (MCK)
Distributes medicines while powering specialty care, medication access, and pharmacy operations.
Something off on this page? Send us feedback.
McKesson is mostly the enormous middleman between medicine makers and the places that care for patients, moving vast sales while keeping only a sliver. It is using that scale to build faster-growing cancer care, research and prescription-access services, while preparing its medical-supply arm to stand more independently.
Item facts: FY2026 · year ended Mar 31, 2026, from filings, earnings calls and company pages.
Judgment weights, not filed revenue
The band summarizes business focus and direction. ~ marks estimates.
5 in detail · 17 more below
North American Pharmaceutical
The enormous base business moved $336.65B of medicine in FY2026, but kept just 1.1 cents of operating profit per revenue dollar. CVS Health alone bought 24%; renewal before June 2027 is the dependency to watch.
Competes with AmerisourceBergen Drug Corporation distribution (Cencora) · Pharmaceutical Distribution Solutions (Cardinal Health)
In plain English
Think of the medicine aisle's wholesale back room. McKesson buys brand-name, generic and other medicines, stores them in distribution centers, then delivers them to pharmacies and health systems when ordered. The customer pays for the products; McKesson keeps a thin slice for sourcing, handling and delivery.
For nearly all brand-name medicine contracts, that slice is a service fee rather than a bet on rising drug prices. So pricier medicine can make sales look much larger without making profit rise nearly as much. The network depends on steady supply and the renewal of a few very large customer agreements.
Oncology & Multispecialty
McKesson's fast-growing second engine combines cancer and specialist medicine delivery with services for independent clinics. Q1 FY2027 revenue jumped 33%, helped by acquisitions; keeping that pace after the deal boost is what matters.
Competes with Oncology Supply and ION Solutions (Cencora) · Navista and VitalSource group purchasing (Cardinal Health)
In plain English
A small cancer clinic needs costly medicines on time, buying power it cannot create alone and help with the paperwork and research around patient care. McKesson supplies all of that: it delivers the drugs, gathers practices into group-buying arrangements, supports clinic operations and connects doctors with studies.
Drug delivery still supplies nearly all the sales. Clinics pay for medicines and some support, while drug makers pay for research and data services. By bringing more community practices into the network, McKesson gains medicine volume and more places to run studies—but rules for what insurers and government programs will pay, along with drug availability, can slow the machine.
Precision Medicine Group
The proposed research-services purchase would stretch McKesson from delivering treatments into helping drug makers test and launch them. The agreed price is $2.25B; closing and then linking it to community clinics are the watchpoints.
Competes with Research & Development Solutions (IQVIA) · Full-service drug development (ICON) · Phase I–IV development (Parexel)
In plain English
Before a new medicine reaches the shelf, its maker must identify the right patients, run studies, handle laboratory work and prove the treatment's value. Precision Medicine Group sells that practical help around the world, from choosing biological clues to organizing trials and launch plans.
McKesson does not own it yet. If the deal closes, drug makers would pay Precision for each research and launch assignment, while McKesson's community clinics could provide study locations, patients and care data. The idea is a longer relationship with medicine makers, but it begins only after the purchase clears.
Medical-Surgical Solutions
This broad catalog of everyday medical supplies made $11.51B in FY2026. After year-end Apollo bought a minority stake; the watchpoint is McKesson's planned separation and staged move to the Wellverse name.
Competes with Physician Office Distribution (Medline) · Distribution Services (Owens & Minor)
In plain English
The unglamorous supplies that keep care moving: gloves, syringes, exam-room equipment and thousands of other products used outside hospital wards. McKesson gathers those items into one enormous catalog, delivers repeat orders to clinics and other care sites, and maintains certain equipment.
Customers pay for the products and the convenience of dependable restocking. Own-brand goods sit beside national brands, giving McKesson another way to earn on the same delivery route. Apollo, an investment firm, became a minority owner after FY2026 as McKesson prepared the business to operate more independently.
Prescription Technology Solutions
This small connector between drug makers, doctors, pharmacies and insurers kept 18.0 cents of operating profit per revenue dollar. Watch whether new medicine launches and access programs replace older programs as they end.
Competes with Electronic Prior Authorization (Surescripts) · Electronic Prior Authorization (DrFirst)
In plain English
A prescription is not useful if insurance permission, price help or delivery gets stuck. This business connects the parties that can unstick it: doctors submit requests, insurers answer, pharmacies fill the order and patients see lower-cost choices.
Drug makers pay McKesson to store and ship medicines and to help patients start treatment; a little over half of the segment's sales come from that storage-and-delivery work. They also fund access programs and software-guided steps such as getting an insurer's approval before a prescription is filled. Revenue can bounce when one program ends before another begins.
North American PharmaceuticalThe enormous base business moved $336.65B of medicine in FY2026, but kept just 1.1 cents of operating profit per revenue dollar. CVS Health alone bought 24%; renewal before June 2027 is the dependency to watch.The enormous base business moved $336.65B of medicine in FY2026, but kept just 1.1 cents of operating profit per revenue dollar. CVS Health alone bought 24%; renewal before June 2027 is the dependency to watch.
In plain English
Think of the medicine aisle's wholesale back room. McKesson buys brand-name, generic and other medicines, stores them in distribution centers, then delivers them to pharmacies and health systems when ordered. The customer pays for the products; McKesson keeps a thin slice for sourcing, handling and delivery.
For nearly all brand-name medicine contracts, that slice is a service fee rather than a bet on rising drug prices. So pricier medicine can make sales look much larger without making profit rise nearly as much. The network depends on steady supply and the renewal of a few very large customer agreements.
Competes with AmerisourceBergen Drug Corporation distribution (Cencora) · Pharmaceutical Distribution Solutions (Cardinal Health)
Oncology & MultispecialtyMcKesson's fast-growing second engine combines cancer and specialist medicine delivery with services for independent clinics. Q1 FY2027 revenue jumped 33%, helped by acquisitions; keeping that pace after the deal boost is what matters.McKesson's fast-growing second engine combines cancer and specialist medicine delivery with services for independent clinics. Q1 FY2027 revenue jumped 33%, helped by acquisitions; keeping that pace after the deal boost is what matters.
In plain English
A small cancer clinic needs costly medicines on time, buying power it cannot create alone and help with the paperwork and research around patient care. McKesson supplies all of that: it delivers the drugs, gathers practices into group-buying arrangements, supports clinic operations and connects doctors with studies.
Drug delivery still supplies nearly all the sales. Clinics pay for medicines and some support, while drug makers pay for research and data services. By bringing more community practices into the network, McKesson gains medicine volume and more places to run studies—but rules for what insurers and government programs will pay, along with drug availability, can slow the machine.
Competes with Oncology Supply and ION Solutions (Cencora) · Navista and VitalSource group purchasing (Cardinal Health)
Precision Medicine GroupThe proposed research-services purchase would stretch McKesson from delivering treatments into helping drug makers test and launch them. The agreed price is $2.25B; closing and then linking it to community clinics are the watchpoints.The proposed research-services purchase would stretch McKesson from delivering treatments into helping drug makers test and launch them. The agreed price is $2.25B; closing and then linking it to community clinics are the watchpoints.
In plain English
Before a new medicine reaches the shelf, its maker must identify the right patients, run studies, handle laboratory work and prove the treatment's value. Precision Medicine Group sells that practical help around the world, from choosing biological clues to organizing trials and launch plans.
McKesson does not own it yet. If the deal closes, drug makers would pay Precision for each research and launch assignment, while McKesson's community clinics could provide study locations, patients and care data. The idea is a longer relationship with medicine makers, but it begins only after the purchase clears.
Competes with Research & Development Solutions (IQVIA) · Full-service drug development (ICON) · Phase I–IV development (Parexel)
Medical-Surgical SolutionsThis broad catalog of everyday medical supplies made $11.51B in FY2026. After year-end Apollo bought a minority stake; the watchpoint is McKesson's planned separation and staged move to the Wellverse name.This broad catalog of everyday medical supplies made $11.51B in FY2026. After year-end Apollo bought a minority stake; the watchpoint is McKesson's planned separation and staged move to the Wellverse name.
In plain English
The unglamorous supplies that keep care moving: gloves, syringes, exam-room equipment and thousands of other products used outside hospital wards. McKesson gathers those items into one enormous catalog, delivers repeat orders to clinics and other care sites, and maintains certain equipment.
Customers pay for the products and the convenience of dependable restocking. Own-brand goods sit beside national brands, giving McKesson another way to earn on the same delivery route. Apollo, an investment firm, became a minority owner after FY2026 as McKesson prepared the business to operate more independently.
Competes with Physician Office Distribution (Medline) · Distribution Services (Owens & Minor)
Prescription Technology SolutionsThis small connector between drug makers, doctors, pharmacies and insurers kept 18.0 cents of operating profit per revenue dollar. Watch whether new medicine launches and access programs replace older programs as they end.This small connector between drug makers, doctors, pharmacies and insurers kept 18.0 cents of operating profit per revenue dollar. Watch whether new medicine launches and access programs replace older programs as they end.
In plain English
A prescription is not useful if insurance permission, price help or delivery gets stuck. This business connects the parties that can unstick it: doctors submit requests, insurers answer, pharmacies fill the order and patients see lower-cost choices.
Drug makers pay McKesson to store and ship medicines and to help patients start treatment; a little over half of the segment's sales come from that storage-and-delivery work. They also fund access programs and software-guided steps such as getting an insurer's approval before a prescription is filled. Revenue can bounce when one program ends before another begins.
Competes with Electronic Prior Authorization (Surescripts) · Electronic Prior Authorization (DrFirst)
Named in filings, launches and programs
- ClarusONEEcosystemA Walmart joint venture that pools purchasing of lower-cost, off-patent medicines for participating retailers.
- McKesson ConnectPlatformThe online storefront where U.S. medicine-distribution customers order products and manage their accounts.
- Health MartEcosystemA franchise and support network for roughly four thousand independent U.S. pharmacies.
- Health Mart AtlasServiceHelps independent pharmacies join insurer networks and manage the related administrative work.
- McKesson CanadaProduct lineThe retained Canadian medicine wholesaling and specialist-services operation after McKesson sold its local retail businesses.
- The US Oncology NetworkEcosystemA community cancer-care network of roughly three thousand four hundred providers treating more than two million patients annually.
- OnmarkServicePools medicine purchasing for independent specialist practices, giving small clinics the buying reach of a larger group.
- Core VenturesBrandA mostly owned administrative-services business established by Florida Cancer Specialists and acquired in June 2025.
- PRISM VisionBrandA mostly owned platform handling the business side of retina and eye-care practices.
- Sarah Cannon Research InstituteServiceA jointly owned clinical-research organization serving community cancer sites, now collaborating with Pfizer on studies.
- OntadaPlatformTurns information from community cancer practices into research and evidence about how treatments work in everyday care.
- InspiroGeneServiceCoordinates delivery and patient access for cell and gene treatments within the cancer and specialty-care business.
- Biologics by McKessonServiceA specialist pharmacy supporting more than two hundred treatments for cancer and rare diseases.
- CoverMyMedsPlatformA network that helps doctors obtain insurer permission and connect patients with prescription-support programs.
- Rx Savings SolutionsPlatformShows people lower-cost prescription choices under their health benefits and helps them navigate the change.
- Medicare GLP-1 Bridge program enablementCustomer program · RampingSupports eligibility checks, insurer permission and claims for Medicare's temporary bridge covering GLP-1 medicines, a class of prescription drugs.
- WellverseBrand · AnnouncedThe future name of Medical-Surgical Solutions, expected to begin formal operation in January 2027 during a phased transition.
ClarusONEEcosystem
A Walmart joint venture that pools purchasing of lower-cost, off-patent medicines for participating retailers.
McKesson ConnectPlatform
The online storefront where U.S. medicine-distribution customers order products and manage their accounts.
Health MartEcosystem
A franchise and support network for roughly four thousand independent U.S. pharmacies.
Health Mart AtlasService
Helps independent pharmacies join insurer networks and manage the related administrative work.
McKesson CanadaProduct line
The retained Canadian medicine wholesaling and specialist-services operation after McKesson sold its local retail businesses.
The US Oncology NetworkEcosystem
A community cancer-care network of roughly three thousand four hundred providers treating more than two million patients annually.
OnmarkService
Pools medicine purchasing for independent specialist practices, giving small clinics the buying reach of a larger group.
Core VenturesBrand
A mostly owned administrative-services business established by Florida Cancer Specialists and acquired in June 2025.
PRISM VisionBrand
A mostly owned platform handling the business side of retina and eye-care practices.
Sarah Cannon Research InstituteService
A jointly owned clinical-research organization serving community cancer sites, now collaborating with Pfizer on studies.
OntadaPlatform
Turns information from community cancer practices into research and evidence about how treatments work in everyday care.
InspiroGeneService
Coordinates delivery and patient access for cell and gene treatments within the cancer and specialty-care business.
Biologics by McKessonService
A specialist pharmacy supporting more than two hundred treatments for cancer and rare diseases.
CoverMyMedsPlatform
A network that helps doctors obtain insurer permission and connect patients with prescription-support programs.
Rx Savings SolutionsPlatform
Shows people lower-cost prescription choices under their health benefits and helps them navigate the change.
Medicare GLP-1 Bridge program enablementCustomer program · Ramping
Supports eligibility checks, insurer permission and claims for Medicare's temporary bridge covering GLP-1 medicines, a class of prescription drugs.
WellverseBrand · Announced
The future name of Medical-Surgical Solutions, expected to begin formal operation in January 2027 during a phased transition.